B-Cell Non-Hodgkin Lymphoma, Bloodstream Infections, CAR-T Cell Therapy, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Conditions
Keywords
Multiple Myeloma, B-cell Non-Hodgkin Lymphoma, CAR-T Cell Therapy, CAR-T Cell Infusion, Bloodstream Infection, Infectious Complications, CAR-T, ddPCR blood test, Cytokine Release Syndrome, CRS
Brief summary
This study includes adults with multiple myeloma or B-cell lymphoma who were/will be treated with CAR-T cell therapy at the IRCCS Azienda Ospedaliero-Universitaria di Bologna. The aim is to better understand infections that may occur during the first year after CAR-T treatment, including how often they happen, their causes, and factors that may increase the risk. The study will use information from patients treated in the past and from newly enrolled patients. For some patients who develop fever after CAR-T therapy, a rapid molecular blood test will be used alongside standard tests to help identify bloodstream infections more quickly and support timely clinical care.
Detailed description
This is a single-center observational study involving adult patients with relapsed/refractory multiple myeloma or B-cell non-Hodgkin lymphoma who received/will receive CAR-T cell therapy at the IRCCS Azienda Ospedaliero-Universitaria di Bologna. The study aims to evaluate how often infections occur during the first 12 months after CAR-T infusion and to describe their main characteristics and risk factors. Both patients treated since 2019 (retrospective cohort) and newly enrolled patients during the year following study approval (prospective cohort) will be included, with one year of follow-up after infusion. The study will investigate factors associated with infection risk, the impact of preventive and therapeutic anti-infective strategies, the distinction between infection-related fever and cytokine release syndrome (CRS), post-discharge infections, and immune recovery after CAR-T therapy. In the prospective cohort, patients who develop their first fever episode after CAR-T infusion will also undergo a validated rapid molecular blood test (PilotGene ddPCR Blood System), alongside standard blood cultures, to improve the speed of bloodstream infection diagnosis. The test is already used in clinical practice and will serve as a complementary diagnostic tool without changing standard patient management. Approximately 290 patients are expected to be included, most of whom with lymphoma.
Interventions
None listed
Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of relapsed/refractory multiple myeloma or B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), high-grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL) * Receipt of CAR-T infusion at IRCCS AOUBo * Age ≥18 years at the time of CAR-T infusion * Signed informed consent
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative Incidence of Participants With at Least One Infectious Complication After CAR-T Infusion. | Within 12 months after CAR-T infusion | Percentage of participants experiencing at least one infectious complication of any type within 12 months after CAR-T infusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adjusted Odds Ratios for Predefined Pre- and Post-Infusion Factors Associated With Infectious Complications. | Within 12 months after CAR-T infusion | Adjusted odds ratios with 95% confidence intervals for the association between predefined pre-infusion and post-infusion variables and the occurrence of at least one infectious complication after CAR-T infusion. |
| Classification of the first febrile episode within 30 days after CAR-T infusion. | Within the first 30 days after CAR-T infusion | Classification of each participant's first febrile episode as no fever, infection-related fever, indeterminate fever, or cytokine release syndrome (CRS)-related fever. |
| Participants with microbiologically documented infection at the first febrile episode. | Within the first 30 days after CAR-T infusion. | Number (or percentage) of participants with a microbiologically documented infection identified at the time of the first febrile episode. |
| Post-Discharge Infectious Complications. | From hospital discharge up to 12 months after CAR-T infusion. | Percentage of participants with at least one infectious complication occurring after hospital discharge. |
| Diagnostic Yield of the Pilot Gene ddPCR Blood Test. | Up to 12 months after enrollment (at the first febrile episode) | Percentage of first febrile episodes with at least one pathogen and/or antimicrobial resistance marker detected by the Pilot Gene droplet digital polymerase chain reaction blood test. |
Countries
Italy
Contacts
CONTACTZeno Adrien Igor Pasquini, MD
CONTACTMaddalena Giannella, MD, PhD
PRINCIPAL_INVESTIGATORZeno Adrien Igor Pasquini
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Outcome results
None listed